Abstract
Heart failure (HF) is a condition associated with the apoptosis and cell death of both cardiac myocytes and cardiac non-myocytes. DNA fragments released from programmed cell death or acute cellular injury are the main sources of disease-associated elevation of cell-free (cf) DNA. We hypothesized that cfDNA could be a relevant marker of cardiac apoptosis in HF patients that could be affected by the improvement of myocardial performance. To test our hypothesis, we measured plasma cfDNA in 19 patients with ischemic HF and severe left ventricular (LV) systolic dysfunction before and 12 h after completion of levosimendan infusion. Echocardiographic and biochemical markers of LV diastolic pressure and LV systolic function were also assessed. In accordance with previous observations levosimendan improved echocardiographic and biochemical indices of LV function. Plasma cfDNA was significantly reduced in HF patients post-levosimendan treatment (median: 89.4, interquartile range: 87.1 to median: 25.9, interquartile range: 12.3, P = 0.028). Notably, in 15/19 patients there was a reduction in cfDNA levels post-levosimendan infusion; while in 12/19 patients, a more than 50% reduction in plasma cfDNA was observed. Since cfDNA is a marker of tissue injury and apoptosis these results indicate that improvement of LV function has a potential impact on cell preservation and survival. Further studies are needed to substantiate our promising results regarding the role of plasma cfDNA as a marker of HF.
Similar content being viewed by others
References
Sozzi G, Conte D, Leon M et al (2003) Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol 21:3902–3908
Chun FK, Muller I, Lange I et al (2006) Circulating tumour-associated plasma DNA represents an independent and informative predictor of prostate cancer. BJU Int 98:544–548
Goebel G, Zitt M, Muller HM (2005) Circulating nucleic acids in plasma or serum (CNAPS) as prognostic and predictive markers in patients with solid neoplasias. Dis Markers 21:105–120
Boddy JL, Gal S, Malone PR, Harris AL, Wainscoat JS (2005) Prospective study of quantitation of plasma DNA levels in the diagnosis of malignant versus benign prostate disease. Clin Cancer Res 11:1394–1399
Jung K, Fleischhacker M, Rabien A (2010) Cell-free DNA in the blood as a solid tumor biomarker—a critical appraisal of the literature. Clin Chim Acta 411(21–22):1611–1624
Gupta AK, Holzgreve W, Huppertz B, Malek A, Schneider H, Hahn S (2004) Detection of fetal DNA and RNA in placenta-derived syncytiotrophoblast microparticles generated in vitro. Clin Chem 50:2187–2190
Bauer M, Hutterer G, Eder M et al (2006) A prospective analysis of cell-free fetal DNA concentration in maternal plasma as an indicator for adverse pregnancy outcome. Prenat Diagn 26:831–836
Zhong XY, Holzgreve W, Hahn S (2002) The levels of circulatory cell-free fetal DNA in maternal plasma are elevated prior to the onset of preeclampsia. Hypertens Pregnancy 21:77–183
Chang CP, Chia RH, Wu TL, Tsao KC, Sun CF, Wu JT (2003) Elevated cell-free serum DNA detected in patients with myocardial infarction. Clin Chim Acta 327:95–101
Raptis L, Menard HA (1980) Quantitation and characterization of plasma DNA in normals and patients with systemic lupus erythematosus. J Clin Invest 66:1391–1399
Uzuelli JA, Dias-Junior CA, Izidoro-Toledo TC, Gerlach RF, Tanus-Santos JE (2009) Circulating cell-free DNA levels in plasma increase with severity in experimental acute pulmonary thromboembolism. Clin Chim Acta 409:112–116
Plenchette S, Filomenko R, Logette E (2004) Analyzing markers of apoptosis in vitro. Methods Mol Biol 281:313–331
Lui YY, Chik KW, Chiu RW, Ho CY, Lam CW, Lo YM (2002) Predominant hematopoietic origin of cf-DNA in plasma and serum after gender-mismatched bone marrow transplantation. Clin Chem 48:421–427
Jahr S, Hentze H, Englisch S et al (2001) DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 61:1659–1665
Sharov VG, Sabbah HN, Shimoyama H et al (1996) Evidence of cardiocyte apoptosis in myocardium of dogs with chronic heart failure. Am J Pathol 148:141–149
Park M, Shen YT, Gaussin V et al (2009) Apoptosis predominates in nonmyocytes in heart failure. Am J Physiol Heart Circ Physiol 297:H785–H791
Vescovo G, Volterrani M, Zennaro R et al (2000) Apoptosis in the skeletal muscle of patients with heart failure: investigation of clinical and biochemical changes. Heart 84:431–437
Altenberger J, Parissis JT, Ulmer H, Poelzl G, LevoRep Investigators (2010) Rationale and design of the multicentre randomized trial investigating the efficacy and safety of pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep study). Eur J Heart Fail 12:186–192
Third Joint Task Force of European, other Societies on Cardiovascular Disease Prevention in Clinical Practice (2003) European guidelines on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prev Rehabil 10:1–78
Sozzi G, Roz L, Conte D et al (2005) Effects of prolonged storage of whole plasma or isolated plasma DNA on the results of circulating DNA quantification assays. J Natl Cancer Inst 97:1848–1850
Sifakis S, Zaravinos A, Maiz N, Spandidos DA, Nicolaides KH (2009) First-trimester maternal plasma cell-free fetal DNA and preeclampsia. Am J Obstet Gynecol 201:472e1–472e7
Chatterjee K, Massie B (2007) Systolic and diastolic heart failure: differences and similarities. J Card Fail 13:569–576
Karatzis EN, Giannakopoulou AT, Papadakis JE, Karazachos AV, Nearchou NS (2009) Myocardial performance index (Tei index): evaluating its application to myocardial infarction. Hellenic J Cardiol 50:60–65
Lee Y, Gustafsson AB (2009) Role of apoptosis in cardiovascular disease. Apoptosis 14:536–548
Hatzistamou J, Kiaris H, Ergazaki M, Spandidos DA (1996) Loss of heterozygosity and microsatellite instability in human atherosclerotic plaques. Biochem Biophys Res Commun 225:186–190
Slawsky MT, Colucci WS, Gottlieb SS et al (2000) Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation 102:2222–2227
Antoniades C, Tousoulis D, Koumallos N, Marinou K, Stefanadis C (2008) Levosimendan: beyond its simple inotropic effect in heart failure. Pharmacol Ther 114:v184–v197
Parissis JT, Andreadou I, Bistola V, Paraskevaidis I, Filippatos G, Kremastinos DT (2008) Novel biologic mechanisms of levosimendan and its effect on the failing heart. Exp Opin Investig Drugs 17:1143–1150
Adamopoulos S, Parissis JT, Iliodromitis EK et al (2006) Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. Am J Cardiol 98:102–106
Parissis JT, Adamopoulos S, Antoniades C et al (2004) Effects of levosimendan on circulating proinflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am J Cardiol 93:1309–1312
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zaravinos, A., Tzoras, S., Apostolakis, S. et al. Levosimendan reduces plasma cell-free DNA levels in patients with ischemic cardiomyopathy. J Thromb Thrombolysis 31, 180–187 (2011). https://doi.org/10.1007/s11239-010-0527-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11239-010-0527-8